Saggar, Rajeev

Liquidia Technologies (United States)

A Phase 3, 2-part, Open-label, Multicenter Study to Evaluate the Safety, and Efficacy of Liposomal Treprostinil Inhalation Suspension (l606) in Subjects With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung

D105. BALBOA PARK EXPLORERS: TRANSLATIONAL SCIENCE AND EPIDEMIOLOGY IN PH | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A7368-A7368

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a7368

Expert Consensus on the Screening, Treatment, and Management of Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD), and the Potential Future Role of Anti-fibrotics[asterisk] in a Treatment Paradigm for SSc-ILD: A Delphi Consens

C101. NON-IDIOPATHIC INTERSTITIAL PNEUMONIA NATURAL HISTORY AND PROGNOSIS AND ILD THERAPY | August 26, 2019 | Volume: No volume available | Issue: No issue available | Pages: A7445-A7445

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a7445

Saggar, Rajeev

Citations 2

A Phase 3, 2-part, Open-label, Multicenter Study to Evaluate the Safety, and Efficacy of Liposomal Treprostinil Inhalation Suspension (l606) in Subjects With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung

Expert Consensus on the Screening, Treatment, and Management of Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD), and the Potential Future Role of Anti-fibrotics[asterisk] in a Treatment Paradigm for SSc-ILD: A Delphi Consens